[Role of advanced practice nurse within a cellular therapy unit: Recommendations of the Francophone Society of Bone Marrow Transplantation and cellular therapy (SFGM-TC)].

Rôle de l’infirmière en pratique avancée (IPA) dans une unité de thérapie cellulaire : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC).
Advanced practice nurse CAR T-cell therapy CAR-T cells Cellular therapy Greffe hématopoïétique Hematopoietic cell transplantation Infirmière Nurse practitioner Pratique avancée Thérapie cellulaire

Journal

Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416

Informations de publication

Date de publication:
14 Feb 2023
Historique:
received: 10 11 2022
revised: 03 01 2023
accepted: 09 01 2023
entrez: 16 2 2023
pubmed: 17 2 2023
medline: 17 2 2023
Statut: aheadofprint

Résumé

Like the "nurse practitioner" in Anglo-Saxon countries, the French health authority validated on January 2016 the creation of an intermediate grade called advanced practice nurse (APN). They are authorized to carry out an assessment of the person's state of health, through a complete clinical examination. They can also prescribe additional examinations necessary for the monitoring of the pathology, and carry out certain acts for diagnostic and/or therapeutic purposes. Given the specificities of cellular therapy patients, the content of university professional training doesn't seem sufficient to assure an optimal management by the APN of these patients. The Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC) had already published two works regarding what was initially called "the transfer of skills" between doctors and nurses in the follow-up of transplant patients. In the same way, this workshop attempts to address the question of the place of APNs in the management of patients undergoing cellular therapy treatment. Beyond a delegation of tasks as proposed by the cooperation protocols, this workshop produces recommendations to allow an autonomous activity of the IPA in the follow-up of these patients, in close collaboration with the medical team.

Identifiants

pubmed: 36797127
pii: S0007-4551(23)00051-6
doi: 10.1016/j.bulcan.2023.01.010
pii:
doi:

Types de publication

English Abstract Practice Guideline

Langues

fre

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Thomas Jezequel (T)

Service d'hématologie, oncologie, immunologie pédiatrique, CHU Nantes, 44093 Nantes cedex 1, France. Electronic address: thomas.jezequel@chu-nantes.fr.

Nathalie Cheron (N)

CH Bligny, 91640 Briis-sous-Forges, France.

Rezarta Ajazi Hub (R)

Institut Bordet, 1070 Bruxelles, Belgique.

Carole Brouillat (C)

I CHU SE, 42000 St.-Etienne, France.

Elodie Colonnese (E)

CHU IUCT Oncopole, 31059 Toulouse, France.

Claire Desmedt (C)

CHU Tours, 37000 Tours, France.

Solène Evard (S)

Service d'oncohématologie pédiatrique, CHU Hôpital sud, 35000 Rennes, France.

Séverine Hie (S)

CHU Lille, 59000 Lille, France.

Cécilia Mourrut (C)

CHU Grenoble-Alpes, 38000 Grenoble, France.

Déborah Vallade (D)

CH Bligny, 91640 Briis-sous-Forges, France.

Isabelle Bouhier (I)

CHU de Nantes, Service de santé publique, 44093 Nantes cedex 1, France.

Céline Chauvel (C)

Gustave-Roussy Cancer Center, 94800 Villejuif, France.

Virginie Gandemer (V)

Service d'oncohématologie pédiatrique, CHU Hôpital sud, 35000 Rennes, France.

Lara Mercier (L)

CHU IUCT Oncopole, 31059 Toulouse, France.

Ibrahim Yakoub-Agha (I)

CHU de Lille, Univ Lille, Inserm U1286, Infinite, 59000 Lille, France.

Classifications MeSH